These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 20638602)

  • 21. [Use of the IgM fraction from patients' sera in general virus serology for diagnostic purposes].
    Wolff MH; Marklein G; Schneweis KE; Stifter G
    Zentralbl Bakteriol Orig A; 1974; 227(1-4):392-400. PubMed ID: 4154618
    [No Abstract]   [Full Text] [Related]  

  • 22. Susceptibility to measles, rubella, mumps, and varicella-zoster viruses among healthcare workers.
    Aypak C; Bayram Y; Eren H; Altunsoy A; Berktaş M
    J Nippon Med Sch; 2012; 79(6):453-8. PubMed ID: 23291844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
    Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of fifteen commercial assays for detecting Varicella Zoster virus IgG with reference to a time resolved fluorescence immunoassay (TRFIA) and the performance of two commercial assays for screening sera from immunocompromised individuals.
    Chris Maple PA; Gunn A; Sellwood J; Brown DW; Gray JJ
    J Virol Methods; 2009 Feb; 155(2):143-9. PubMed ID: 18996415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of measles, rubella, mumps, and varicella antibodies among healthcare workers in Japan.
    Hatakeyama S; Moriya K; Itoyama S; Nukui Y; Uchida M; Shintani Y; Morisawa Y; Kimura S
    Infect Control Hosp Epidemiol; 2004 Jul; 25(7):591-4. PubMed ID: 15301032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiplex Bead Assay for the Serological Surveillance of Measles and Rubella.
    Coughlin MM; Smits G; Matson Z; van Binnendijk R; Bankamp B
    Methods Mol Biol; 2024; 2808():225-246. PubMed ID: 38743374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of measles, mumps and rubella viruses by immuno-colorimetric assay and its application in focus reduction neutralization tests.
    Vaidya SR; Kumbhar NS; Bhide VS
    Microbiol Immunol; 2014 Dec; 58(12):666-74. PubMed ID: 25244651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rubella susceptibility predicts measles susceptibility: implications for postpartum immunization.
    Libman MD; Behr MA; Martel N; Ward BJ
    Clin Infect Dis; 2000 Dec; 31(6):1501-3. PubMed ID: 11096023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
    Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
    J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The prevalence of measles, rubella, mumps and chickenpox antibodies in a population of health care workers].
    Oliveira J; da Cunha S; Côrte-Real R; Sampaio L; Dais N; Meliço-Silvestre A
    Acta Med Port; 1995 Apr; 8(4):206-16. PubMed ID: 7625214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility of medical students to vaccine-preventable viral diseases: a serological study.
    Kukino J; Naito T; Mitsuhashi K; Oshima H; Sekiya S; Isonuma H; Watanabe K; Dambara T; Hayashida Y
    J Infect Chemother; 2004 Dec; 10(6):335-7. PubMed ID: 15614457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of IgM enzyme immunoassay and IgG avidity assay for distinguishing between primary and secondary immune response to rubella vaccine.
    Hamkar R; Jalilvand S; Mokhtari-Azad T; Nouri Jelyani K; Dahi-Far H; Soleimanjahi H; Nategh R
    J Virol Methods; 2005 Dec; 130(1-2):59-65. PubMed ID: 16026863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific and non-specific B cell activation in measles and varicella.
    Arneborn P; Biberfeld G; Forsgren M; von Stedingk LV
    Clin Exp Immunol; 1983 Jan; 51(1):165-72. PubMed ID: 6299636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of molecular testing to confirm measles, mumps and rubella in immunised individuals.
    Speers DJ; Dowse GK
    Med J Aust; 2015 Apr; 202(6):297-8. PubMed ID: 25832147
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.